Compare Ascendis Pharma A/S (ASND) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while YieldMax TSLA Option Income Strategy ETF trades at $27.24. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | TSLY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $48.25 |
52-Week Low | $163.32 | $26.16 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TSLY trades at $27.42, down slightly by 0.04% today, with a bearish technical signal from moving averages and key indicators like ADX. The ETF generates high income through weekly distributions, with recent payouts ranging from $0.28 to $0.52 per share. Support levels are at $26 and $27, while resistance lies near $28 and $29. Recent news highlights consistent dividend announcements from YieldMax, reinforcing its income-focused strategy.
The outlook for TSLY hinges on its ability to sustain high distributions amid market volatility. While the ETF offers attractive yield potential, risks include capped upside from covered call strategies and sensitivity to Tesla's stock performance. Investors should weigh income benefits against volatility and capital erosion risks in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
